Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1 by Kato Yukio et al.
Gene knockout and metabolome analysis of
carnitine/organic cation transporter OCTN1
著者 Kato Yukio, Kubo Yoshiyuki, Iwata Daisuke,
Kato Sayaka, Sudo Tomohisa, Sugiura Tomoko,
Kagaya Takashi, Wakayama Tomohiko, Hirayama
Akiyoshi, Sugimoto Masahiro, Sugihara Kazushi,
Kaneko Shuichi, Soga Tomoyoshi, Asano
Masahide, Tomita Masaru, Matsui Toshiyuki,













Gene Knockout and Metabolome Analysis of 
Carnitine/Organic Cation Transporter OCTN1 
 
 
Yukio Kato,1 Yoshiyuki Kubo, 1 Daisuke Iwata, 1 Sayaka Kato, 1 Tomohisa Sudo, 1 Tomoko Sugiura, 1 
Takashi Kagaya, 2 Tomohiko Wakayama, 3 Akiyoshi Hirayama, 4 Masahiro Sugimoto, 4 Kazushi 
Sugihara, 5 Shuichi Kaneko, 2 Tomoyoshi Soga, 4 Masahide Asano, 5 Masaru Tomita, 4 Toshiyuki Matsui, 
6 Morimasa Wada, 7 and Akira Tsuji1,8
 
 
1Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa 
University, Kanazawa 920-1192, Japan, 2Department of Gastroenterology, Kanazawa University 
Hospital, Kanazawa 920-0934, Japan, 3Department of Histology and Embryology, Graduate School of 
Medical Science, Kanazawa University, Kanazawa 920-0934, Japan, 4Institute for Advanced 
Biosciences, Keio University, Yamagata 997-0035, Japan, 5Division of Transgenic Animal Science, 
Advanced Science Research Center, Kanazawa University, Kanazawa 920-0934, Japan, 6Department of 
Gastroenterology, Fukuoka University Chikushi Hospital, Fukuoka 818-8502, Japan, 7Division of 
Molecular Biology, Faculty of Pharmaceutical Sciences, Nagasaki International University, Nagasaki 






Running Head: Gene Knockout and Metabolome Analysis of OCTN1 
 
 
Correspondence:  Prof. Akira Tsuji, Ph.D., Division of Pharmaceutical Sciences, Graduate School of 
Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.  




Purpose:  Solute carrier, OCTN1 (SLC22A4) is an orphan transporter, the physiologically important 
substrate of which is still unidentified. The aim of the present study was to examine physiological roles 
of OCTN1. 
Methods: We first constructed octn1 gene knockout (octn1-/-) mice. Metabolome analysis was then 
performed to identify substrates in vivo. The possible association of the substrate identified with 
diseased conditions was further examined.  
Results:  The metabolome analysis of blood and several organs indicated complete deficiency of a 
naturally occurring potent antioxidant ergothioneine in octn1-/- mice among 112 metabolites examined. 
Pharmacokinetic analyses after oral administration revealed the highest distribution to small intestines 
and extensive renal reabsorption of [3H]ergothioneine, both of which were much reduced in octn1-/- mice. 
The octn1-/- mice exhibited greater susceptibility to intestinal inflammation under the ischemia and 
reperfusion model. The blood ergothioneine concentration was also much reduced in Japanese patients 
with Crohn’s disease, compared with healthy volunteers and patients with another inflammatory bowel 
disease, ulcerative colitis. 
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Conclusions:  These results indicate that OCTN1 plays a pivotal role for maintenance of systemic and 
intestinal exposure of ergothioneine which could be important for protective effect against intestinal 
tissue injuries, providing a possible diagnostic tool to distinguish the inflammatory bowel diseases. 
 




Carnitine/organic cation transporter OCTN1 (SLC22A4) was originally identified in our 
laboratory as a multispecific transporter which preferentially recognizes organic cations and, to a lesser 
extent, carnitine, which is essential for β-oxidation of fatty acids in mitochondria, as substrates (1,2). In 
addition, Gründemann et al have previously reported that ergothioneine is also the good substrate for 
OCTN1 in vitro, by utilizing cell biological and metabolomics approaches (3). Despite the previous 
identification of various substrates for OCTN1 in in vitro experimental systems, biologically important 
substrates for OCTN1 in vivo have not yet been clarified. OCTN2 (SLC22A5) is another member of the 
OCTN family and is much more carnitine-selective (4,5). A physiologically pivotal role of OCTN2 in 
reabsorption of carnitine in proximal tubules has already been identified: a missense mutation in the 
octn2 gene of a naturally occurring mutant, juvenile visceral steatosis (jvs) mouse, or in the OCTN2 gene 
of humans leads to systemic carnitine deficiency (6).  
Both OCTN1 and OCTN2 genes are located on cytokine cluster region in chromosome 5q, which 
is possibly associated with various inflammatory diseases. OCTN1 gene was actually reported to be 
associated with rheumatoid arthritis (7), whereas both OCTN1 and OCTN2 genes have been proposed to 
contribute directly to susceptibility to Crohn’s disease (CD) in European people (8). However, the 
reported mutations in these genes (C1672T and G-207C, respectively) were absent or not associated 
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with CD in Japanese patients (9), supporting the existence of ethnic difference in genetic variants 
causative of CD. In addition, the variants in these two genes appeared not to be causative even in 
European populations according to a recent analysis of more than a thousand pairs (10). Thus, the 
precise locus directly linked to CD susceptibility has not yet been elucidated, probably because of the 
limitations of a purely genetic approach. 
Considering the association of the OCTN2 gene with CD (8), experimental animals with mutation 
of the octn2 gene would be useful tools to explore the pathogenesis of CD. This idea is supported by 
recent findings of spontaneous development of intestinal atrophy and inflammation in jvs mice, 
demonstrating an obligatory role of OCTN2 in the maintenance of normal intestinal morphology (11). 
On the other hand, little is known about the physiological role of OCTN1, mainly because appropriate 
gene-deficient animals are not available. In the present study, we first developed octn1 gene knockout 
(octn1-/-) mice with the aim of employing them to examine the biological roles and possible association 
of OCTN1 with any diseased conditions. The metabolome analysis using capillary electrophoresis 
time-of-flight mass spectrometry (CE-TOFMS) of blood and several organs indicated complete 
deficiency in octn1-/- mice of a naturally occurring potent antioxidant ergothioneine which was found to 
be highly accumulated in small intestine after oral administration. The greater susceptibility to intestinal 
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inflammation in the octn1-/- mice and the lower blood levels of ergothioneine in Japanese CD patients 











Materials and Methods 
Construction of octn1 Gene Knockout (octn1-/-) Mice.  
The octn1-/- mice were generated according to the method previously reported (12). PCR was 
first performed with genomic DNA derived from E14-1 ES cells in order to isolate the homologous 
regions of octn1 gene. The targeting vector consisted of 8.5 kb of the 3' homologous region, 1.2 kb of 
the 5' homologous region of octn1gene, the neomycin resistance (Neor) gene cassette driven under the 
phosphoglycerate kinase I promoter (13) and subunit A of the diphtheria toxin (DT-A) gene cassette 
driven under the MC1 promoter (14). With this targeting vector, exon 1 (including the start codon) 
should be deleted (Supplementary Figure 1). The vector construction and purification was performed by 
means of E. coli DH5α. The linearized targeting vector (20 μg) was then electroporated into ES cells, 
and recombinants were selected with 180 mg/mL of active form G418 (Gibco/BRL) for 7 - 10 days. 
More than 500 clones of embryotic stem cells were screened by genomic PCR. Three of them were 
subjected to Southern blot analysis, and two clones (1B5 and 3B3) were selected to generate octn1-/- 
mice (Supplementary Figure 1B). Chimeric mice were generated by the aggregation method. Chimeras 
were mated with C57BL/6J females, and homozygous mutant mice were generated by crossing of the 
heterozygotes. Mice were given normal commercial diet, PicoLab Rodent Diet 20 (PMI Nutrition 
International, St. Louis, MO), and water ad libitum. They were kept in an environmentally controlled 
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clean room at the Institute of Experimental Animals, Advanced Science Research Center, Kanazawa 
University. 
Genotypes in mice were determined by a PCR method using genomic DNA prepared from 
mouse ear. The forward primer (5’-catttcagaagtaaagaaaccctgcgag-3’) was localized outside the targeting 
vector, whereas the reverse primer outside exon 1 (5’-gaaagtgggggcctcgacatag-3’) or that at the end of 
the PGKneobpA cassette (5’-ctatggcttctgaggcggaaagaacc-3’) was used to detect wild-type and mutant 
locus, respectively (Supplementary Figure 1A). PCR was carried out for 40 cycles at 94°C for 30 sec, 
64°C for 30 sec and 72°C for 2.5 min using a Platinum PCR SuperMix (Invitrogen). Deletion of the 
octn1 gene and loss of expression of the gene product in kidney membrane fraction of octn1-/- mice were 
confirmed (Supplementary Figure 1C and D). All the animal experiments were performed according to 
the Guidelines for the Care and Use of Laboratory Animals in Kanazawa University.  
 
Southern blot analysis. 
Southern blot was performed as previously described (15). Genomic DNA prepared from mouse 
liver was digested with Xba I, electrophoresed through a 0.8% agarose gel, and transferred to 
Hybond-N+ (GE Healthcare). Hybridization was carried out using 32P-labeled DNA probes made by 




Western blot analysis.  
Western blot was performed as previously described (15). The membrane fraction prepared from 
mouse kidneys were separated by 12% SDS-polyacrylamide gel, followed by the transfer of the proteins 
to polyvinylidene difluoride membrane (Immobilon, Millipore). The membrane was incubated with 
polyclonal anti-peptide antibodies against the carboxyl terminus of mouse OCTN1 for 2 hr, and then 
incubated with secondary antibody (donkey anti-rabbit IgG, horseradish peroxidase-linked whole 
antibody, GE Healthcare). The proteins were detected by means of the enhanced chemiluminescence 
detection method using the ECL Plus Western-blotting detection system (GE Healthcare). 
 
Differential metabolomics. 
The wild-type and octn1-/- mice were fasted overnight with free access to water and then 
anesthetized with pentobarbital (60 mg/kg), followed by collection of urine from a bladder cannula for 
30 min. Blood and tissues were then obtained, and metabolites were extracted and subjected to 





Analysis of ergothioneine by means of HPLC. 
All the tissue samples were weighed, and portions were homogenized with two volumes of 
distilled water. The homogenized tissues, urine, plasma and blood were deproteinized with acetonitrile 
and subjected to HPLC after centrifugation. The HPLC system incorporated a model PU-2080 pump and 
a model UV-2075 monitor (Jasco) with a 250 x 4.6 mm i.d. Atlantis HILIC silica column (Waters). The 
mobile phase was 0.1 M ammonium formate and methanol at a ratio of 95:5. The flow rate was 1 
mL/min. The wavelength for UV detection was 268 nm. Cephaloridine was used as the internal 
standard. 
 
Pharmacokinetic study in mice. 
Male mice (8 weeks old) were fasted overnight with access to water, and anesthetized by 
intraperitoneal injection of pentobarbital. After oral administration of [3H]ergothioneine (Moravek 
Biochemicals) at 330 µg/kg, each mouse was kept in a metabolic cage during the experiment. Blood 
samples were collected from the tail vein using heparinized capillary tubes at 1 h, and 1, 2, 3, 5, 7, 10 
and 14 days under anesthesia. Urine samples were collected using a metabolic cage. Plasma, blood and 
urine samples were mixed with scintillation fluid (Clearsol, Nakarai Tesque) for quantitation. At 14 days, 
tissues were excised, rinsed with ice-cold saline, blotted to dryness and weighed. Tissue samples 
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(0.05-0.2 g) were dissolved in 1 mL of Soluene-350 (Packard), mixed with scintillation fluid, and 
neutralized with 5 M HCl, followed by determination of the associated radioactivity.  
 
Intestinal ischemia and reperfusion injury. 
Male mice (10-12 weeks old) were fasted for 18-20 hr with free access to water and anesthetized 
by intraperitoneal injection of pentobarbital. A midline laparotomy was performed, and the superior 
mesenteric artery was occluded with an arterial microclamp. Intestinal ischemia was confirmed by 
pulselessness of the mesentery and paleness of the intestine. After 60 min the clamp was removed, and 
the mice were sutured. Intestinal tissue sections were deparaffinized, rehydrated and stained with 
hematoxylin and eosin. Differences in survival of wild-type and octn1-/- mice were determined by means 
of the log-rank test. Statistical analysis was performed using GraphPad Prism version 4.0 (GraphPad 
Software San Diego). 
 
Transport studies in renal brush border membrane vesicles 
The brush border membrane vesicles were prepared essentially as previously described with a 




Blood sampling in humans. 
Unrelated Japanese adult patients with CD (n = 25, 14 ~ 47 years old, 18 male and 7 female) and 
ulcerative colitis (UC, n = 16, 18 ~ 70 years old, 8 male and 8 female) were enrolled from Kanazawa 
University Hospital. Unrelated Japanese adult healthy volunteers (n = 31, 21 ~ 36 years old, 22 male 
and 9 female) were recruited from Kanazawa University Hospital and the Faculty of Pharmaceutical 
Sciences, Kanazawa University. Informed consent was obtained from all the subjects. The study 
protocol was approved by the ethics committee of Kanazawa University Graduate School of Medical 
Science (Kanazawa, Japan) and the study was carried out in accordance with the Declaration of 
Helsinki. Blood samples (5 ~ 10 mL) were drawn from the brachial vein of the subjects. Statistical 
analysis was performed by means of one-way ANOVA followed by Dannett’s multiple comparison 
test. 
 
Genotyping in human samples.  
Blood samples were obtained from Japanese adult patients (N = 256) with CD in Kanazawa 
University Hospital, Kyushu University Hospital and Fukuoka University Hospital. DNA was isolated 
using the QIAamp DNA Blood Mini Kit (QIAGEN, Tokyo, Japan). The DNA sequence was analyzed 
by sequence-specific PCR using the primers shown in Supplementary Table 1. The genomic sequencing 
14 
 
was performed for all the exons of OCTN1 and OCTN2. Since several introns can also be sequenced by 
the primers used in the present study, allelic frequency of such introns was also analyzed. The SNP at 
the 5’-UTR region of OCTN2 (G-207C) was previously reported to be associated with CD in Caucasians 
(8), and was also analyzed in the present study. Exon 1 of OCTN1, and the 5’-UTR and exon 1 of 
OCTN2 were amplified in a total volume of 25 µl, with 5 ng of genomic DNA, 10 µM of each 
amplification primer, 2.5 mM of each dNTP, 2 x GC rich buffer I and 1.25 units of LA Taq DNA 
polymerase (TaKaRa). The PCR reaction was initial denaturation at 94 oC for 2 min, followed by 35 
cycles of denaturation at 94 oC for 30 s, annealing for 30 s and extension at 72 oC, and a final extension 
at 72 oC for 7 min. The annealing temperature and extension time are shown in Supplementary Table 1. 
Other regions were amplified in a total volume of 25 µL, with 5 ng of genomic DNA, 10 µM of each 
amplification primer, 2.5 mM of each dNTP, 5 x Expand High Fidelity Reaction buffer without 7.5 mM 
MgCl2 and 2.5 units of Expand High Fidelity Enzyme Blend (Roche). All samples were sequenced using 
a BigDye Terminator v3.1 Cycle Sequencing Kit (ABI PRISM). The sequence reaction was initiated by 
denaturation at 96 oC for 2 min, followed by 35 cycles of 96 oC for 10 s, 50 oC for 5 sec and 60 oC for 1 
min, and a final extension at 60 ℃ for 7 min. All samples were confirmed by sequencing on an ABI 
310 DNA sequencer (Applied Biosystems). The study protocol was approved by the ethical committees 




Metabolome analysis revealed complete loss of ergothioneine in the octn1-/- mice. 
Targeted disruption of the octn1 gene was first performed by homologous recombination. The 
octn1-/- mice thus obtained were born at the expected Mendelian ratio (Supplementary Figure 1E), 
developed normally and did not display any gross phenotypic abnormalities. Most of the biochemical 
parameters of sera examined exhibited minimal difference between wild-type and octn1-/- mice, and 
some parameters exhibited minor, but significant difference only in female mice (Supplementary Table 
2). To identify any possible phenotypes observed in the octn1-/- mice, we then applied a metabolome 
differential display method based on capillary electrophoresis time-of-flight mass spectrometry 
(CE-TOFMS) (16) to compare the metabolites of wild-type and octn1-/- mice. Only ergothioneine was 
found to be completely absent in erythrocytes of octn1-/- mice (Supplementary Figure 2). In this analysis, 
we quantitatively measured 112 metabolites by means of CE-TOFMS (16,17) and confirmed the loss of 
ergothioneine in heart, liver, small intestine, kidney and erythrocytes of octn1-/- mice (Figure 1). 
Ergothioneine level was further examined in various tissues, plasma and urine by means of HPLC, 
confirming complete loss of ergothioneine in all the tissue samples examined and plasma of octn1-/- 




Ergothioneine is a substrate of mouse OCTN1 
When mouse OCTN1 or OCTN2 was heterologously transfected in HEK293 cells, only 
OCTN1, but not OCTN2 efficiently transports ergothioneine as a substrate (Figure 2A), as previously 
reported for human and rat OCTN1 (3,19). The uptake of [3H]ergothioneine by mouse OCTN1 was 
saturable with Km and Vmax values of 4.68 µM and 532 pmol/min/mg protein, respectively (Figure 2B) 
and reduced by the replacement of Na+ in the medium (Figure 2C). 
 
Intestinal absorption, distribution to small intestine and renal reabsorption of ergothioneine 
In general, ergothioneine is known as an extremely stable antioxidant which can directly 
scavenge reactive oxygen species, thereby protecting tissues against oxidative stress (20,21). Due to the 
minimal endogenous biosynthesis, the major source of ergothioneine for animals and plants is fungi and 
mycobacteria in soil (21). Because quite limited information is available on details in biodistribution 
kinetics of ergothioneine in the body, we next examined the absorption and disposition of 
[3H]ergothioneine after oral administration. The plasma concentration of [3H]ergothioneine transiently 
increased and then gradually decreased in octn1-/- mice, whereas that in wild-type mice was maintained 
for at least two weeks after oral administration (Figure 3A). This result was compatible with the much 
higher accumulation of [3H]ergothioneine also in erythrocytes of wild-type mice (Figure 3B). The 
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disappearance of [3H]ergothioneine in octn1-/- mice could be due to the higher urinary excretion in 
octn1-/- mice, compared with wild-type mice (Figure 3C). Overshoot uptake of [3H]ergothioneine was 
observed in renal brush-border membrane vesicles prepared from wild-type mice, but not in octn1-/- 
mice (Supplementary Figure 3). This suggests that ergothioneine is reabsorbed by OCTN1 in wild-type 
mice, but not in octn1-/- mice if we consider that OCTN1 is localized on brush-border membranes of 
proximal tubules (22). 
The tissue distribution of [3H]ergothioneine after oral administration was then analyzed in both 
strains (Figure 4). The highest concentration of [3H]ergothioneine was observed in upper and middle 
parts of small intestine at 4 hr after oral administration in wild-type mice (Figure 4A). However, such 
accumulation in small intestine cannot be observed in octn1-/- mice (Figure 4A). The distribution of 
[3H]ergothioneine to small intestine and other tissues was observed even at 14 days after oral 
administration in wild-type mice, but the distributed amount was much smaller in octn1-/- mice (Figure 
4B). 
 
The octn1-/- mice showed a lower tolerance to intestinal oxidative stress. 
Ergothioneine concentration in the small intestine was approximately 0.1 mM (~20 µg/mL, 
Table I). At such a concentration, ergothioneine behaves as a powerful chemical scavenger of a number 
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of oxidizing species (23). In addition, ergothioneine was found to be highly accumulated in small 
intestine (Figure 4), and exogenous administration of ergothioneine was reported to ameliorate oxidative 
stress in various tissues, including small intestine (24). These data led us to examine whether or not 
octn1-/- mice were more sensitive to small intestinal injury. For this purpose, ischemia and reperfusion 
were performed to generate a small-intestinal inflammatory model in mice (Figure 5). After the 
reperfusion, lethality was significantly higher in the octn1-/- mice than in wild-type mice (Figure 5A). 
This was consistent with the more obvious loss of villus structures in small intestine of octn1-/- mice 
(Figure 5B). 
 
Decreased blood levels of ergothioneine in CD patients. 
The apparently greater susceptibility of octn1-/- mice to intestinal inflammation (Figure 5) further 
led us to examine a possible association of ergothioneine and inflammatory bowel disease in humans as 
well. As shown in the Table I, the blood samples in mice showed 16.5 µg/mL of ergothioheine, whereas 
the plasma ergothioneine concentration was much lower and close to the detection limit of HPLC, 
suggesting that the blood samples would be more useful for the comparison of the ergothioneine level 
between healthy volunteers and patients. Therefore, the ergothioneine concentration in blood of CD and 
UC patients was next examined by means of HPLC. As a result, CD patients exhibited much lower 
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ergothioneine concentration in blood than healthy volunteers or patients with UC (Figure 6). Among the 
CD patients examined in the present study, no remarkable difference in the blood ergothioneine 
concentration was observed between patients with and without food restriction. 
 
Genotyping of patients with CD.  
To examine a direct linkage between CD and the OCTN1 gene in the patients examined in the 
present study, we sequenced all the exon regions of the OCTN1 and OCTN2 genes, determined the 
allelic frequency in CD patients for SNPs reported in the NCBI database, and then compared the results 
with those in healthy volunteers. The mutations reported to be associated with CD patients in Caucasians 
(C1672T/L503F in OCTN1 and G-207C in OCTN2) (8) were completely absent in Japanese CD patients 
examined in the present study (Supplementary Table 3). Furthermore, no other allelic frequencies 




In the present study, octn1-/- mice were constructed to identify the in vivo substrates of OCTN1 
with an aim to understand physiological roles of this transporter. Ergothioneine was identified as a 
physiological substrate of OCTN1 in the metabolome analysis (Figure 1). Ergothioneine was previously 
identified as a substrate of OCTN1 in gene transfectant systems in vitro (3) and, therefore, was 
examined similarly to other over 100 compounds in the metabolome analysis. Ergothioneine has the 
potent antioxidant property, and the source of ergothioneine in human and animals is solely food intake 
due to the minimal biosynthesis (20,21). Although the mice were given normal diets without any 
modification in the present study, ergothioneine was detected in their tissues. It would be possible that 
the normal diets contained considerable amount of ergothioneine because of food chain resultant and/or 
contamination. The highest accumulation of ergothioneine in small intestine after oral administration 
(Figure 4) implies that ergothioneine may protect against oxidative stress in this tissue. The slightly, but 
significantly lower tolerance to intestinal oxidative stress in octn1-/- mice (Figure 5) supports such 
anti-oxidant activity exerted by ergothioneine and further led us to examine the linkage between 
ergothioneine and CD patients (Figure 6). The diagnosis of CD is empirically based on endoscopic, 
radiologic and histological criteria (25). On the other hand, the present finding proposes ergothioneine as 
a quantitative diagnostic marker to distinguish CD from healthy subjects and UC (Figure 6). It may be 
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noteworthy that ergothioneine level in blood of UC patients is not so far away from that in healthy 
volunteers (Figure 6), indicating specificity of the blood ergothioneine level between the two 
inflammatory bowel diseases. As far as our knowledge, there has been no report indicating such 
quantitative markers which are closely relevant to CD and can be easily determined in patients. Thus, 
combination of gene knockout and metabolome analysis has finally revealed the basis for a diagnostic 
tool to distinguish CD from UC and healthy condition. 
The present study has also proposed a close interrelationship between OCTN1 and ergothioneine. 
Ergothioneine has unique feature in its pharmacokinetics: Plasma and blood concentration of 
ergothioneine is maintained at least for 14 days in wild-type mice after a single oral administration 
(Figure 3A and B). This is probably because of large tissue distribution, tissue-to-plasma concentration 
ratio being more than 10 in small intestines, liver and kidney (Figure 4A), but small urinary excretion of 
ergothioneine, the amount excreted for 14 days after oral administration being at most 10% of dose in 
wild-type mice (Figure 3C). On the other hand, the plasma and blood concentration of ergothioneine 
transiently increased and then gradually decreased in octn1-/- mice after oral administration (Figure 3A 
and B) due to much lower tissue distribution (Figure 4) and much higher urinary excretion (Figure 3C). 
The transient increase in plasma and blood concentration of ergothioneine in octn1-/- mice, which 
appeared to be absent in wild-type mice (Figure 3A and 3B) could be explained by the remarkable 
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difference in the distribution of ergothioneine to the liver (Figure 4A): The Kp value in the liver 
exhibited approximately 200 times difference between wild-type and octn1-/- mice (Figure 4A). This 
may support the hypothesis that the liver plays a first-pass elimination organ in wild-type mice, but not 
in octn1-/- mice, although this hypothesis should be verified by the further analyses. The higher urinary 
excretion of ergothioneine in octn1-/- mice would be due to reabsorption of ergothioneine by OCTN1 if 
we consider that OCTN1 is localized on brush-border membranes of proximal tubules (22), can 
transport ergothioneine (Figure 2) and is involved in influx of ergothioneine in renal brush-border 
membrane vesicles (Supplemental Figure 3). Both ergothioneine level (Table I) and tissue distribution of 
[3H]ergothioneine exogenously administered (Fig. 4) were almost completely reduced in octn1-/- mice, 
and this was compatible with ubiquitous expression of OCTN1 in all the tissues examined (1). Thus, 
OCTN1 is involved in both tissue distribution and renal reabsorption of ergothioneine, thereby 
contributing to maintain steady-state ergothioneine level in the body. 
It may be noteworthy that the wild-type mice showed distinct kinetics in the ergothioneine 
concentration between the plasma and blood: Ergothioneine level in blood increased slowly and reached 
the plateau at 6 days whereas plasma ergothioneine level was high at 1-3 days (Figure 3A and B). It was 
suggested that OCTN1 is highly expressed in glycophorin A-positive erythroid cells and possibly 
associated with erythroid-lineage cells at the transition stage from immature erythroid cells to peripheral 
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mature erythrocytes (26). Combined with the present results, it can be speculated that ergothioneine is 
taken up to the hematopoietic cells during their differentiation stage. The slow increase in the 
ergothioneine level in the blood (Figure 3B) could reflect the gradual increase in the number of matured 
blood cells containing [3H]ergothioneine. 
In addition to the close interrelationship with OCTN1, ergothioneine seems to be relevant to a 
certain intestinal inflammatory status. This hypothesis was supported by the lower ergothioneine level in 
CD patients than healthy volunteers (Figure 6) and slightly lower tolerance to intestinal oxidative stress 
in octn1-/- mice (Figure 5) in which ergothioneine level was under the detection limit (Table I).  
Exogenous administration of ergothioneine was reported to ameliorate oxidative stress in various tissues, 
including small intestine (24). Therefore, the effect of ergothioneine treatment on clinical symptoms of 
CD patients needs to be examined to clarify whether ergothioneine has a potential ameliorating effect on 
the intestinal inflammation. The pharmacokinetic analysis in the present study indicated that 
ergothioneine is orally absorbed even in octn1-/- mice (Figure 3A and B), suggesting that ergothioneine 
exogenously administered could be exposed inside the small intestinal epithelium even when OCTN1 is 
functionally defective. While ergothioneine is generally though to work as antioxidant in the body, its 
actual function in vivo has been questioned, indicating the possibility that ergothioneine has other 
unknown function directly related to CD. However, identification of the biological activities of 
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ergothioneine has been hindered by the absence of experimental animals deficient in ergothioneine. 
Because the present study has revealed minimal presence of ergothioneine in octn1-/- mice, but much 
higher concentration (µM or mM level) of ergothioneine in wild-type mice (Table I), this octn1-/- mice 
may be a suitable tool to demonstrate diverse activities of ergothioneine in vivo. 
In present study, the contribution of other transporter(s) was also implied to the membrane 
permeation of ergothioneine. For example, ergothioneine was substantially taken up by the mock cells 
without transfection of OCTN1 gene (Figure 2B), and octn1-/- mice showed a transient increase in the 
plasma and blood level of ergothioneine after oral administration (Figure 3A and B). In addition, 
significant difference was observed in ergothioneine level between CD patients and other groups (Figure 
6), but the difference was not so obvious, compared with that observed between wild-type and octn1-/- 
mice (Table I). Therefore, it is possible that other transporter(s) than OCTN1 may contribute to 
ergothioneine transport in the body. Further studies will be needed for its molecular identification. 
Gene knockout mice has been widely applied to analyze the roles of transporters, but often 
exhibits minimal phenotype in the knockout mice possibly due to the compensation by other transporter 
gene products in vivo and/or functional redundancy provoked by homologous transporters with 
overlapped substrate specificity (27,28). This may be also true for OCTN1, if we consider minimal 
phenotype found in octn1-/- mice at least in normal breeding condition (see Results). Thus, application of 
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the metabolomics approach would be a powerful tool to identify any phenotypic difference between 
wild-type and the knockout mice. Metabolome analysis has been recently established to simultaneously 
measure whole metabolite profiles in the body, and application of this technology to whole organs of the 
gene knockout animals may identify physiologically important substrates, providing a clue to understand 
any physiological relevance of the transporters. 
The possible association between CD and OCTN1 was not fully demonstrated in the present 
study. Association between OCTN1 gene and CD had been controversial, and this could be compatible 
with the present finding that the mutations reported to be associated with CD patients in Caucasians 
were completely absent in Japanese CD patients (Supplementary Table 3), and that no allelic 
frequencies exhibited a clear difference between CD patients and healthy volunteers (Supplementary 
Table 3). However, steady-state ergothioneine level appears to be governed by OCTN1 according to the 
present findings (Table I). In addition, since ergothioneine is minimally biosynthesized or metabolized 
in animals (20,21,29,30), transporter(s) involved in its absorption and disposition would be likely to 
regulate the steady-state level of ergothioneine. Therefore, it is necessary to directly examine the 
function of OCTN1 in CD patients to clarify the possible relation between the lower ergothioneine level 
in CD patients (Figure 6) and OCTN1 activity in those patients.  
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In conclusion, combination of two biotechnological tools, gene knockout and metabolome 
analysis, has revealed pivotal role of OCTN1 in ergothioneine homeostasis which could be related to 




CD, Crohn’s disease; UC, ulcerative colitis; OCTN, Organic carnitine/organic cation transporter; 
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Legends to Figures 
 
Fig. 1. Metabolome analysis revealed almost complete loss of ergothioneine in octn1-/- mice 
The data shown represent the heat map indicating overall difference in the amount of 112 
metabolites in each tissue and erythrocytes between wild-type and octn1-/- mice. Each column in the 
abscissa represents expression index which scales relative amount of the metabolite in each tissue and 
erythrocytes of wild-type mice to that in octn1-/- mice (N = 3 for each strain). Each column in the 
ordinate represents each metabolite, and the arrowhead indicates erghothioneine. 
 
Fig. 2. Uptake of [3H]ergothioneine by mouse OCTN1 
(A) Time course of [3H]ergothioneine uptake by mouse OCTN1. HEK293 cells were transiently 
transfected with OCTN1 (open circles), OCTN2 (open triangles) or vector alone (closed circles), and 
uptake of [3H]ergothioneine (3.4 µM) was then measured over 10 min at pH 7.4. The uptake was 
expressed as cell-to-medium ratio, which was obtained by dividing the amount taken up in the cells by 
substrate concentration in the medium. Each value represents the mean ± SEM (n = 3). When error bars 
are not shown, they are smaller than the symbols. 
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(B) Concentration dependence of [3H]ergothioneine uptake by mouse OCTN1. Uptake of various 
concentrations of [3H]ergothioneine was measured over 5 min at pH 7.4. The closed and open circles 
represent the uptake by HEK293 cells expressing OCTN1 and vector alone, respectively. Each line was 
obtained by nonlinear least-squares analysis. A solid line represents the OCTN1-mediated uptake after 
subtraction of the uptake by mock cells from that by OCTN1-expressing cells.  
(C) Sodium dependence of [3H]ergothioneine uptake by mouse OCTN1. Uptake of [3H]ergothioneine 
was measured over 5 min at pH 7.4 in the presence (closed columns) or absence (open columns) of Na+. 
In the absence of Na+, Na+ was replaced with N-methyl-D-glucamine. 
 
Fig. 3. Absorption and disposition of [3H]ergothioneine after oral administration.  
[3H]Ergothioneine was orally administered in wild-type (open circles) and octn1-/- (closed circles) mice, 
and plasma (A) and blood (B) concentrations, and cumulative urinary excretion (C) were determined for 
14 days. Each value represents the mean ± SEM (n = 3 - 6).  
 
Fig. 4. Ergothioneine is highly distributed to small intestine after oral administration  
[3H]Ergothioneine remaining in plasma and tissues was determined 4 hrs (A) and 14 days (B) after oral 
administration in wild-type (open bars) and octn1-/- (closed bars) mice. The data showing the 
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tissue-to-plasma concentration ratio less than 10 were enlarged in the inlet of panel A. Each value 
represents the concentration ratio between the indicated tissue and plasma, and is shown as mean ± SEM 
(n = 3 - 4). 
*, Significantly different from wild-type mice by Student’s t test (p < 0.05). 
 
Fig. 5. Ergothioneine protects small intestine from lethal injury. 
(A) Survival curves of wild-type (n=6, open) or octn1-/- mice (n=7, closed) after ischemia (60 min) and 
reperfusion. P < 0.05 (log-rank test).  
(B) Histology of the intestinal mucosa. Wild-type (left) and octn1-/- (right) mice were subjected to gut 
ischemia-reperfusion. At 30 min after reperfusion, the intestine was removed and stained with H&E. 
Original magnification, x 200 
 
Fig. 6. Ergothioneine concentration in blood of healthy volunteers (n = 31), patients with CD (n = 
25) and those with UC (n = 16) 
The horizontal lines and squares within each box represent the median and the arithmetic mean, 
respectively. The box edges show the lower (25th) and upper (75th) quartiles. The whiskers extend 
from the 25th and 75th quartiles to the furthest data points within a distance of 1.5 interquartile ranges 
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from the 25th and 75th quartiles. Circles outside whiskers represent outliers. Statistical comparisons 
were performed using one-way ANOVA with Dannett’s multiple comparison test.*, Significantly 


























































































































































































































































































































































































































































































Births (M / F)
Total
89 (41 / 48)
145 (69 / 76)
84 (41 / 43)















Generation of octn1   mice (A) Targeted disruption of the slc22a4/octn1 gene by 
homologous recombination. The PGKneobpA cassette (Neo) and the DT-A cassette (DT-A) are 
indicated with white arrows. Exon 1 of the octn1 gene, which includes the start codon, is shown 
as a closed box. PCR primers used for screening are shown as arrows. The black bars show the 
positions of external probes used for Southern blot analysis. (B) Southern blot analysis of ES cell 
clones. Genomic DNA (10 µg) from ES cell clones (1B5, 3B2, 3B3) was digested with Xba I and 
hybridized with the probe. The expected DNA fragments for the mutant (Mt) and wild-type (Wt) 
alleles are indicated (11.1 and 19.6 kb, respectively).(C) Southern blot analysis of wild-type and 
octn1    mice. Genomic DNA (10 µg) from liver was digested with Xba I and hybridized with the 
probe. The expected DNA fragments for the mutant and wild-type alleles are indicated.(D) 
Western blot analysis of wild-type and octn1    mice. The lysates of membrane fraction obtained 
from kidneys were loaded onto SDS-PAGE. Slc22a4/Octn1 protein was detected with a rabbit 
anti-Octn1 antibody. A band (arrow), which corresponds to the molecular mass of Octn1 (70 kD), 








Metabolomic analysis in octn1   mice. The data shown represent a typical 
result for detection of cationic metabolites in erythrocytes of wild-type (A) 
and octn1   (B)  mice. In panel (C), metabolome differential displays are 
shown, and the gradation of the color bar indicates increase (red) or 
decrease (blue) of the metabolite level in octn1    mice. Ergothioneine in 






































Time course of [ H]ergothioneine uptake by brush border membrane 
vesicles (BBMVs) of wild-type and octn1   mice. Membrane vesicles 
were suspended in the buffer (pH 7.4). Uptake of [ H]ergothioneine (3.4 µM) 
by BBMVs of wild-type (open circles) and octn1    (closed circles) mice were 
measured at 25 ° C in the uptake buffer at pH 7.4. Data were expressed as 
vesicle-to-medium ratio, which was obtained by dividing the amount taken 
up in the vesicles by substrate concentration in the uptake medium. Each 
result represents the mean ± S. E. M. (n = 3).
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